Pharmaceutical

MC-232 by MC2 Therapeutics for Hidradenitis Suppurativa: Likelihood of Approval

MC-232 is under clinical development by MC2 Therapeutics and currently in Phase II for Hidradenitis Suppurativa.

Oct 3, 2023 - 20:00
MC-232 is under clinical development by MC2 Therapeutics and currently in Phase II for Hidradenitis Suppurativa.
Read the original article

Tags:

Previous Article

Super DC Vaccine by Shanghai Cell Therapy Group for Solid Tumor: Likelihood of A...

Next Article

CD123-targeted CAR-NK by Chongqing Precision Biotech for Natural Killer Cell Lym...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Celiac study examines precisely how gluten triggers injury to intestine

Celiac study examines precisely how gluten triggers inj...

Jul 14, 2023

STAT+: Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace

STAT+: Patent thickets and terminal disclaimers: How ph...

Dec 21, 2023

Morning Rounds: Americans’ health is trending downward, poll finds

Morning Rounds: Americans’ health is trending downward,...

Dec 15, 2023